Financial Statements for the Year Ended 30 September 2018

for

Four Pharmaceuticals Limited

Contents of the Financial Statements for the Year Ended 30 September 2018

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4

Four Pharmaceuticals Limited

Company Information for the Year Ended 30 September 2018

DIRECTORS:	Mrs JE Raine P Raine
SECRETARY:	Mrs JE Raine
REGISTERED OFFICE:	23 Upper Green Road Tewin Welwyn Hertfordshire AL6 0LE
REGISTERED NUMBER:	03430250 (England and Wales)
ACCOUNTANTS:	Nicholsons Chartered Accountants 1st Floor Bridge House 25 Fiddlebridge Lane Hatfield

Hertfordshire AL10 0SP

Balance Sheet 30 September 2018

		2018		2017	
FIVED ACCETO	Notes	£	£	£	£
FIXED ASSETS Tangible assets	4		346,179		346,430
CURRENT ASSETS	_				
Debtors Cash at bank	5	1,606 21,963 23,569		2,110 <u>16,977</u> 19,087	
CREDITORS	•	45.045		45.000	
Amounts falling due within one year NET CURRENT ASSETS TOTAL ASSETS LESS CURRENT	6	15,045_	8,524	15,329	3,758
LIABILITIES			354,703		350,188
CREDITORS Amounts falling due after more than one					
year NET ASSETS	7		15,000 339,703		15,000 335,188
CAPITAL AND RESERVES Called up share capital	8		2		2
Retained earnings SHAREHOLDERS' FUNDS	-		339,701 339,703		335,186 335,188

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at
- the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Balance Sheet - continued 30 September 2018

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 14 June 2019 and were signed on its behalf by:

Mrs JE Raine - Director

Notes to the Financial Statements for the Year Ended 30 September 2018

1. STATUTORY INFORMATION

Four Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is derived from pharmaceutical consultancy services and is recognised by reference to the stage of completion of the service, exclusive of discounts, rebates and Vat. Other operating income represents rental income received from letting the company's two residential properties and is recognised as rents fall due.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on reducing balance

Computer equipment - 33% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year-end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Page 4 continued...

Notes to the Financial Statements - continued for the Year Ended 30 September 2018

2. ACCOUNTING POLICIES - continued

Investment properties

Investment property is included at fair value. Any surplus or deficit arising from changes in fair value is recognised in the Income Statement.

The fair value gains or losses do not represent distributable profits and so they are credited to a separate fair value reserve.

Depreciation is not provided on the investment properties, which is a departure from the Companies Act 2006. In the opinion of the directors, the properties are primarily investments and so their current value is of more significance than any measure of consumption; consequently, they believe that any depreciation charge would distort the true and fair view presented by the accounts and therefore the accounts do not include a depreciation charge in respect of these properties.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2017 - NIL).

4. TANGIBLE FIXED ASSETS

Long and Computer leasehold fittings equipment £ £ £	Totals £
COST	
At 1 October 2017	252.005
and 30 September 2018 <u>337,178</u> <u>9,314</u> <u>6,403</u> DEPRECIATION	<u>352,895</u>
At 1 October 2017 - 312 6,153	6,465
Charge for year - 1 250	251
At 30 September 2018 - 313 6,403	6,716
NET BOOK VALUE	
At 30 September 2018 337,178 9,001 -	346,179
At 30 September 2017 <u>337,178</u> 9,002 <u>250</u>	346,430
5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	
2018	2017
£	£
Trade debtors 1,162	1,269
Other debtors444	841
<u> 1,606</u>	<u>2,110</u>
6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	
2018	2017
£	£
Taxation and social security 1,229	1,711
Other creditors 13,816	<u>13,618</u>
<u> 15,045</u>	<u> 15,329</u>

Page 5 continued...

Notes to the Financial Statements - continued for the Year Ended 30 September 2018

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2018	2017
	£	£
Other creditors	<u> 15,000</u>	15,000

8. CALLED UP SHARE CAPITAL

Allotted, issu	ied and fully paid:			
Number:	Class:	Nominal	2018	2017
		value:	£	£
2	Ordinary	£1	2	2

9. RELATED PARTY DISCLOSURES

The company is controlled by its directors.

During the year, the company borrowed £200 from (2017: repaid £10,827 to) the directors. At the balance sheet date, the company owed £26,672 (2017: £26,472) to the directors. No terms have been laid down as to repayment of capital or payment of interest on this loan, save that the directors have agreed not to seek repayment of £15,000 (2017: £15,000) of their loan within twelve months of the balance sheet date.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.